Anakinra
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Anakinra: From Rheumatoid Arthritis to Pyogenic Autoinflammatory Syndrome
One-Sentence Summary
Anakinra is a recombinant human interleukin-1 receptor antagonist (IL-1Ra) approved internationally for rheumatoid arthritis and autoinflammatory conditions, but not currently registered on the Australian Register of Therapeutic Goods (ARTG). Among 10 TxGNN-predicted indications, Pyogenic Autoinflammatory Syndrome (PAPA/PAPASH spectrum) emerges as the most clinically actionable candidate, supported by 19 publications including a systematic scoping review — the strongest evidence level (L3) and the only “Proceed with Guardrails” recommendation in this analysis.
Note on TxGNN ranking: The highest TxGNN score belongs to extracutaneous mastocytoma (rank #1, 99.93%), however that indication is purely computational with no supporting literature or trials (L5, Hold). This report focuses on the highest-evidence, most actionable predicted indication — Pyogenic Autoinflammatory Syndrome (rank #9, L3).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not registered on ARTG; approved internationally for Rheumatoid Arthritis and Systemic JIA (USA/EU) |
| Predicted New Indication (Best Evidence) | Pyogenic Autoinflammatory Syndrome (PAPA/PAPASH spectrum) |
| TxGNN Prediction Score | 99.83% (rank #9 within this pack; top TxGNN score is extracutaneous mastocytoma at 99.93%) |
| Evidence Level | L3 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the current evidence pack. Based on established scientific literature, Anakinra is a recombinant form of the naturally occurring human IL-1 receptor antagonist (IL-1Ra). It competitively blocks binding of both IL-1α and IL-1β to the IL-1 type I receptor (IL-1RI), suppressing downstream pro-inflammatory cascades — including NF-κB activation, prostaglandin synthesis, and cytokine amplification — that drive tissue damage in IL-1-mediated diseases.
Pyogenic Autoinflammatory Syndrome, most prominently PAPA syndrome (Pyogenic Arthritis, Pyoderma Gangrenosum, and Acne) and related entities such as PAPASH and PASH, arises from heterozygous mutations in the PSTPIP1 gene. These mutations produce a hyperphosphorylated PSTPIP1 protein that constitutively activates the NLRP3 inflammasome, driving caspase-1 activation and excessive IL-1β secretion. The mechanistic alignment with Anakinra’s target is direct: blocking the IL-1 receptor addresses the terminal effector of this pathological cascade. Published systematic case series (PMID 38259483) and individual case reports confirm clinical responses in patients refractory to conventional therapy.
The broader scientific framework further supports this link. IL-1 has been described as a “master cytokine” of innate immune dysregulation across a wide range of conditions (PMID 24275598), and overproduction of IL-1β is a consistent molecular signature across the PSTPIP1-spectrum diseases. This makes Anakinra a biologically rational and clinically meaningful candidate, even in the absence of formal registered clinical trials for these rare conditions.
Clinical Trial Evidence
Currently no registered clinical trials have been identified for Anakinra in Pyogenic Autoinflammatory Syndrome or the broader PAPA/PAPASH spectrum.
This reflects the rarity of these conditions rather than a negative clinical signal. Rare autoinflammatory syndromes typically progress from case reports and case series directly to compassionate access and registry data, bypassing formal Phase 2/3 trials. Regulatory pathways via the TGA Special Access Scheme (SAS) or Authorised Prescriber programme may be applicable.
Literature Evidence
Showing top 10 publications for Pyogenic Autoinflammatory Syndrome (19 total retrieved):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38259483 | 2024 | Systematic Scoping Review | Frontiers in Immunology | Comprehensive review of anakinra and canakinumab in PSTPIP1-associated inflammatory diseases (PAPA/PAPASH); confirms IL-1 pathway inhibitors are effective in this spectrum |
| 39006661 | 2024 | Case Report | Cureus | Anakinra in PAPASH spectrum disorder; documents clinical response, noting IL-1β overproduction via PSTPIP1 dysregulation as the core mechanism |
| 24275598 | 2013 | Review | Seminars in Immunology | IL-1 as a master cytokine of systemic and local inflammation; catalogues the broadening list of IL-1-driven diseases responsive to targeted therapy |
| 21532836 | 2010 | Review | Current Genomics | PAPA syndrome: PSTPIP1 mutations → inflammasome activation → IL-1β overproduction; establishes the molecular rationale for IL-1 receptor antagonism |
| 22161697 | 2012 | Case Series | Arthritis and Rheumatism | Five PAPA syndrome patients: genotype-phenotype correlations, immunophenotyping, and treatment responses documented in detail |
| 38006373 | 2023 | Case Report | Acta Dermatovenerologica Croatica | PAPA syndrome: challenges achieving long-term remission; anakinra discussed as a treatment option in PSTPIP1-mutant disease with sustained IL-1β overproduction |
| 27448064 | 2016 | Review | Der Hautarzt | Severe acne as a symptom of autoinflammatory diseases (PASH/PAPASH); IL-1β involvement and use of anakinra in selected autoinflammatory syndromes |
| 29742056 | 2018 | Review | Clinical and Experimental Rheumatology | Autoinflammatory diseases: innate immunity dysregulation, IL-1β as a key effector, dermatologic manifestations, and treatment approaches |
| 34778321 | 2021 | Case Report | Frontiers in Medicine | PSTPIP1-associated inflammatory disease (PAID): renal involvement; IL-1 blockers form the cornerstone of treatment for this spectrum |
| 28251506 | 2017 | Case Report | Infection | PAPA syndrome: differential diagnosis from septic arthritis via synovial cell counts; clinical presentation and workup described |
Australia Market Information
Anakinra is not currently listed on the Australian Register of Therapeutic Goods (ARTG). There are 0 ARTG entries.
For Australian patients, the following access pathways may apply:
| Pathway | Description |
|---|---|
| TGA Special Access Scheme (SAS) Category B | Individual patient application for unapproved therapeutic goods; requires documented unmet need |
| TGA Authorised Prescriber | Suitable for specialists managing multiple rare autoinflammatory disease patients |
| Clinical Trial | Participation in an ANZCTR- or ClinicalTrials.gov-registered study |
Overseas registrations for reference:
- USA (FDA): Kineret® approved for Rheumatoid Arthritis; also indicated for Neonatal-Onset Multisystem Inflammatory Disease (NOMID)
- EU (EMA): Approved for Rheumatoid Arthritis, Systemic JIA, NOMID/CAPS, and Still’s disease
- Typical formulation: subcutaneous injection, 100 mg/day for adults (brand: Kineret®, Swedish Orphan Biovitrum)
Safety Considerations
Please refer to the overseas Product Information (PI) for Kineret® (Swedish Orphan Biovitrum AB) for full safety information, as Anakinra is not currently ARTG-registered and Australian PI data is not available in this evidence pack.
Key safety considerations for IL-1 receptor blockade in clinical practice include:
- Serious infections: IL-1 contributes to innate immunity; blockade may impair defence against bacterial and fungal pathogens
- Neutropenia: Monitor full blood count (FBC) including neutrophil count before and during therapy
- Injection-site reactions: Common with subcutaneous administration; typically manageable
- Tuberculosis reactivation risk: Screening recommended prior to initiation (consistent with other biologics)
Conclusion and Next Steps
Decision: Proceed with Guardrails (for Pyogenic Autoinflammatory Syndrome — PAPA/PAPASH spectrum)
Rationale: PSTPIP1 mutations directly drive constitutive IL-1β overproduction via inflammasome hyperactivation, placing Anakinra’s mechanism in direct alignment with the core pathology; a systematic scoping review (2024) and multiple case series provide L3-level evidence of clinical efficacy in colchicine-refractory patients with no alternative biological options.
To proceed, the following is needed:
- Genetic testing to confirm PSTPIP1 mutation in candidate patients (prerequisite for diagnosis)
- TGA Special Access Scheme (SAS) Category B application with documented unmet clinical need
- MOA data retrieval from DrugBank API (currently not available in this evidence pack)
- Safety monitoring plan: FBC with neutrophil differential at baseline and regularly during treatment; infection surveillance; injection-site monitoring
- Multidisciplinary team engagement: rheumatology, dermatology, and clinical genetics
- Baseline tuberculosis screening and infection risk assessment
- Review of the full Kineret® Product Information (PI) for dosing, contraindications, and special populations
Summary of All 10 Predicted Indications
| Rank | Disease | TxGNN Score | Evidence Level | Recommendation |
|---|---|---|---|---|
| 1 | Extracutaneous Mastocytoma | 99.93% | L5 | Hold |
| 2 | Hepatic Infarction | 99.89% | L5 | Hold |
| 3 | Autosomal Recessive Familial Mediterranean Fever | 99.89% | L3 | Research Question |
| 4 | Aggressive Systemic Mastocytosis | 99.88% | L4 | Hold |
| 5 | Hepatic Veno-Occlusive Disease | 99.88% | L5 | Hold |
| 6 | Peliosis Hepatis | 99.85% | L5 | Hold |
| 7 | Oligoarticular JIA (ANA−) | 99.85% | L4 | Research Question |
| 8 | Oligoarticular JIA (ANA+) | 99.85% | L4 | Research Question |
| 9 | Pyogenic Autoinflammatory Syndrome | 99.83% | L3 | Proceed with Guardrails |
| 10 | Unclassified Autoinflammatory Syndrome | 99.81% | L3 | Research Question |
This report is generated for research purposes only and does not constitute medical advice. All repurposing candidates require clinical validation before any therapeutic application. Australian prescribers should consult current TGA guidance for access to non-registered therapeutics.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.